Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04194944 · OUTCOME

Intracranial DOR Per RANO-BM by BICR (With or Without Pembrolizumab)

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer · Source last updated 2025-10-21

This outcome was registered, but no numerical results were posted in the captured record.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Date of Intracranial CR or PR to Date of CNS Progression or Death Due to Any Cause Up to 31 Months

What was measured

Intracranial DOR per RANO-BM by BICR (with or without Pembrolizumab)

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
anticipated Posting Date
2026-06
denom Units Selected
Participants
description
Intracranial DOR per RANO-BM by BICR (with or without Pembrolizumab)
reporting Status
NOT_POSTED
time Frame
Date of Intracranial CR or PR to Date of CNS Progression or Death Due to Any Cause Up to 31 Months
title
Intracranial DOR Per RANO-BM by BICR (With or Without Pembrolizumab)
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice